Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy-Reference-Cited by-同舟云学术

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

Published:2018-01 Issue:1 Volume:19 Page:74-83.e11
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Felip Enriqueta,Hirsh Vera,Popat Sanjay,Cobo Manuel^ORCID,Fülöp Andrea,Dayen Charles,Trigo José M.,Gregg Richard,Waller Cornelius F.,Soria Jean-Charles,Goss Glenwood D.,Gordon James,Wang Bushi,Palmer Michael,Ehrnrooth Eva,Gadgeel Shirish M.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. Metastatic non–small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Reck;Ann Oncol,2014

2. Treatment of advanced squamous cell carcinoma of the lung: a review;Derman;Transl Lung Cancer Res,2015

3. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far;Xu;Ther Clin Risk Manag,2016

4. TECENTRIQ (atezolizumab) injection, for intravenous use [prescribing information],2016

5. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker;Solca;J Pharmacol Exp Ther,2012

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance;Pharmaceuticals;2023-11-03

2. Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer;Pharmaceutics;2023-04-16

3. Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit;Annals of Oncology;2023-04

4. Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review;Frontiers in Immunology;2023-01-10

5. Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life;Journal of Healthcare Engineering;2021-12-13